Redeye comments on the collaboration with University of Washington.
Addlife levererade en stabil rapport för det första kvartalet.
Redeye has interviewed Freemelt’s regional presidents of the Americas and EMEA.
Starbreeze's revenues exceeded our expectations for the quarter by 53%.
Redeye gives its initial comments on the Q1 2024 report from Precise Biometrics, which came in above...
Redeye comments on Physitrack’s soild Q1 figures, which were in line with our expectations.
Redeye in this note briefly comments on Acconeer's Q1'24 report, which came in better than expected.
Redeye provides its initial take on Acarix's Q1 report.
Q1 adj. EBIT of GBP 34m, above ABGSCe at GBP 20m Record high AUM, Valkyrie integrated Strong Q1, sto...
Redeye comments on EG7’s Q1-results which came in below our expectations, mainly due to soft perform...
Redeye comments on Maximum Entertainment ahead of Q1-results (due 21 May) which we expect to be a ba...
First IPU design win with Tier 1 server OEM We lift '26e EBIT by 111% New guidance implies P/E of 3.
Earlier-than-expected cost synergies led to 4% EBITA beat We lift '24e-'26e EBITA by 3-4% on lower o...
Sales -4% vs. ABGSCe but adj. EBIT +1% in Q1 We cut sales by 5% and adj.
Redeye provides its view of Active Biotech's first quarter report of 2024.
In its Q124 report, IRLAB recapped its efforts in targeting major aspects of Parkinson’s disease (PD...
Redeye raises its Base Case and forecasts following a strong Q1 report, with the strong gross margin...
Redeye returns following IRLAB's Q1 report and the news of a development collaboration related to IR...
2024 kan bli ett mellanår med strategiska förändringar i fokus.
Över lag kom kvartalet in under Analysguidens prognos, förklarat av en generell konjunkturnedgång.
